MEMED DIAGNOSTICS LTD

Their core work

MeMed develops host immune-response diagnostic tests that distinguish bacterial from viral infections, helping clinicians decide whether antibiotics are needed. Their core technology analyzes the patient's immune signature rather than trying to identify the pathogen directly, addressing the critical problem of antibiotic overuse and antimicrobial resistance. Through their H2020 projects, they moved from clinical validation of their biomarker platform through to market adoption and broader diagnostic applications, including respiratory and COVID-era diagnostic uncertainty.

What they specialise in

How they've shifted over time

MeMed's H2020 trajectory shows a classic deep-tech commercialization arc. Their early work (2015-2018) focused on clinical validation of their core biomarker technology for respiratory infections, establishing scientific evidence. By 2020, their focus had shifted to broader market applications and health-economic impact, with DECODE targeting diagnostic uncertainty more generally — likely accelerated by the COVID-19 pandemic's spotlight on infection diagnostics.

MeMed is moving from proving their technology works to proving it saves money and improves outcomes at scale, positioning for broad clinical adoption across multiple infection types.

How they like to work

MeMed exclusively coordinates — all three projects have them in the lead role, indicating a company that drives its own R&D agenda rather than joining others' initiatives. Their consortia are small and focused (5 unique partners across 3 countries), suggesting they select specific clinical or technical partners for targeted validation work rather than building large multi-stakeholder networks. This is typical of a product-focused SME that uses EU funding to de-risk commercialization of its own technology.

MeMed maintains a compact network of 5 partners across 3 countries, consistent with focused clinical validation partnerships rather than broad consortium-building. As an Israeli company, their European collaborations likely involve clinical sites and regulatory expertise needed for EU market entry.

What sets them apart

MeMed occupies a distinctive niche: rather than detecting specific pathogens, their platform reads the host's immune response to determine infection type. This approach sidesteps the limitations of pathogen-based tests (which miss unknown or co-infections) and directly answers the clinician's core question: does this patient need antibiotics? Their consistent EU funding across three successive projects — totaling over €6M — signals strong validation of both the technology and its market potential.

Highlights from their portfolio

• Respiratory-ImmunoDx
  Largest single grant (€2.9M) for clinical validation of the core bacterial-vs-viral biomarker signature in respiratory infections.
• DECODE
  Most recent project (2020) with €2.5M, expanding the diagnostic platform beyond respiratory infections to address broader diagnostic uncertainty — likely pandemic-influenced timing.
• AutoPilot-Dx
  Bridges the gap between clinical validation and market: explicitly focused on fast-tracking adoption and improving antibiotic stewardship.